Recent Interviews

Ryan Jackson, CEO, Newlox Gold Ventures Corp.

Ryan Jackson
CEO | Newlox Gold Ventures Corp.
60 Laurie Crescent, V7S 1B7 West Vancouver (CAN)

+1 778 738 0546

Newlox CEO Ryan Jackson on building a green gold producer with a rapid growth trajectory

Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company

Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential

04. March 2020 | 07:27 CET

Medigene, Memphasys, Qiagen - which stocks belong in the portfolio?

  • Medical
Photo credits:

In times of price fluctuations, so-called 'buy on dips' strategy can be an effective method of achieving a favorable entry price for listed companies. Global trends as a framework can be decisive for a successful investment decision. For a modern society, the healthcare sector has become a particularly important sector. In addition to the desire for a long life with health and care, there is also an increasing demand for products and therapies that can fulfil couples' desire to have children. There is a broad spectrum and as an investor it is worth taking a look at the companies.

time to read: 1 minutes by Mario Hose



Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author

In the fight against cancer

The name Medigene is certainly known to many traders. The German biotech company is engaged in therapies for the treatment of various types of cancer in different stages. The T-cell-focused immune therapies are the focus of Medigene. Starting in the field of blood cancers, the company is pursuing a strategy of initiating its own clinical development programmes.

In addition, therapeutic approaches are being sought with selected partners to enable successful treatment of tumors. The market value of Medigene is currently around EUR 110 million. The Medigene share is an investment in cancer research.

Increasing the chances of having children

More and more couples worldwide are desperately longing in vain for a child of their own. Modern medicine has developed various possibilities and procedures to successfully initiate pregnancy. The so-called in vitro fertilisation, also known as IVF procedure, is one possibility of artificial insemination. In this procedure, the ovum is taken from the woman and then artificially fertilized with the man's sperm in the laboratory. If the fertilization is successful, the embryos can then be transferred to the uterus so that pregnancy can begin.

In order to increase the chances of a successful pregnancy, the separation of high-quality sperm is purposeful. The Australian company Memphasys has developed a product that can be used to process the seminal fluid to increase the birth rate. The product called FELIX is currently being tested by experts and sales are expected to start in the second half of 2020. Memphasys currently has a market value of around EUR 25 million. The Memphasys shares enable investors to support couples' desire to have children and benefit from the success of the product.

Expert in molecular information

In connection with the current corona virus, the biotech company Qiagen can offer test solutions that can diagnose whether a patient is infected within an hour. The company is represented in 25 countries around the globe and employs 4,700 people.

According to Medigene, the company offers 500 products that enable physicians, scientists and laboratory staff to examine and research the molecules of the human body for various purposes. The company has more than 500,000 customers in its more than 30-year history. The market value of Qiagen is currently EUR 7.3 billion. Qiagen's stock is the focus of the hype surrounding the current corona virus and a takeover bid by Thermo Fisher. Investors can see price gains.


Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author

Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.

Related comments:

05. May 2020 | 08:33 CET | by Mario Hose

Evotec, Medigene, Memphasys - the right investment timing

  • Medical

The health sector has been in the focus of investors not only since the outbreak of the corona pandemic. The pursuit of a healthy and long life is the motivation for research and development around the globe. In addition to Europe and the USA, Australia as a continent is also a location for ideas and innovations. Investors usually always ask the same questions. How expensive and how long does it take to develop the drug or solution and how big is the market. The bigger the problem or need to be treated, the more lucrative it is.


24. April 2020 | 07:36 CET | by Mario Hose

BioNTech, Gilead, Memphasys - in the spotlight of investors overnight

  • Medical

There are topics and products that are the focus of general interest overnight. Often these are needs or problems that require a time-critical solution. The current situation surrounding the spread of the Corona Virus COVID-19 has brought numerous companies into the focus of investors in recent weeks. The backgrounds are of a very different nature. On the one hand, there are manufacturers of masks, disinfectants or respiratory equipment, as well as medical companies that may have an active ingredient for the prevention or therapy of the Corona Virus on offer. But there are also topics that are beyond the general interest and represent a huge market.


15. January 2020 | 07:42 CET | by Mario Hose

Fresenius Peer: Will the analysts' favorite M1 Kliniken 2020 take off?

  • Medical

Besides Fresenius, M1 Klinken AG is one of the few listed clinic operators in Germany. Unlike the clinic group, M1 has specialised in a lucrative niche: the beauty market. More and more people are helping with beauty and are generating billions in sales in the industry. In just a few years, M1 has become the market leader for beauty medicine in Germany. A growth rate of 30% is also targeted for the future. Foreign business is increasingly becoming the growth driver. After a continuous price increase between 2016 and 2018, the share has consolidated in 2019. But operationally things are still running smoothly. Analysts see more than 50% upside potential.